Indication and Usage for Lung Cancer patients
TARCEVA monotherapy is indicated for the treatment of
patients with locally advanced or metastatic non-small cell lung cancer after
failure of at least one prior chemotherapy regimen.
Results from two, multicenter, placebo-controlled, randomized, Phase 3 trials
conducted in first-line patients with locally advanced or metastatic NSCLC
showed no clinical benefit with the concurrent administration of TARCEVA with
platinum-based chemotherapy [carboplatin and paclitaxel or gemcitabine and
cisplatin] and its use is not recommended in that setting.
More information is available at